<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>STTR Phase I:  Designer peptide opsonins against COVID-19</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>12/15/2020</AwardEffectiveDate>
<AwardExpirationDate>05/31/2022</AwardExpirationDate>
<AwardTotalIntnAmount>255933.00</AwardTotalIntnAmount>
<AwardAmount>255933</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Kaitlin Bratlie</SignBlockName>
<PO_EMAI>kbratlie@nsf.gov</PO_EMAI>
<PO_PHON>7032922638</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact / commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to develop a new therapeutic for the SARS-CoV-2 virus causing COVID-19.  The proposed technology is a novel therapeutic engineered to specifically target the coronavirus and assemble on its surface, disabling the virusâ€™ infectivity. This therapeutic will potentially protect COVID-19 patients with mild to moderate symptoms from worsening and possibly transmitting the virus. The therapy may later benefit asymptomatic or non-infected high-risk groups as well. &lt;br/&gt;&lt;br/&gt;This Small Business Technology Transfer (STTR) Phase I project will study the nature of supramolecular assembly of self-assembled peptides (SAPs) on the surface of pathogens such as the COVID-19 virus (SARS-CoV-2) and its impact on the impairment and immune recognition of the pathogen. Self-assembled peptides have greater stability than unfunctionalized peptides, yet they are twenty times smaller than antibodies. Therefore, they may combine key benefits of antibodies and small molecules, enabling a new modality designed for rapid and affordable widespread development of urgently needed therapies.  Current repurposing efforts are limited by a lack of specificity, while SARS-CoV-2-specific efforts are dominated by antibodies or proteins that are challenging to rapidly manufacture at scale. We will: (1) engineer functionalized anti-COVID-19 SAPs and studying their binding kinetics to the SARS-CoV-2 viral spike protein receptor binding domain (RBD); (2) investigate the in vitro efficacy of anti-COVID-19 SAPs in inhibiting viral infection; and (3) establish the in vitro cytocompatibility and in vivo dose range tolerability of the SAPs.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>12/17/2020</MinAmdLetterDate>
<MaxAmdLetterDate>07/16/2021</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2032392</AwardID>
<Investigator>
<FirstName>Rajesh</FirstName>
<LastName>Dave</LastName>
<PI_MID_INIT>N</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Rajesh N Dave</PI_FULL_NAME>
<EmailAddress>dave@njit.edu</EmailAddress>
<PI_PHON>9735965860</PI_PHON>
<NSF_ID>000423510</NSF_ID>
<StartDate>01/11/2021</StartDate>
<EndDate/>
<RoleCode>Co-Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Vivek</FirstName>
<LastName>Kumar</LastName>
<PI_MID_INIT>A</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Vivek A Kumar</PI_FULL_NAME>
<EmailAddress>vak@njit.edu</EmailAddress>
<PI_PHON>9735965577</PI_PHON>
<NSF_ID>000742260</NSF_ID>
<StartDate>12/17/2020</StartDate>
<EndDate>01/11/2021</EndDate>
<RoleCode>Former Co-Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Amanda</FirstName>
<LastName>Acevedo-Jake</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Amanda Acevedo-Jake</PI_FULL_NAME>
<EmailAddress>aaj@saphtx.com</EmailAddress>
<PI_PHON>6786131386</PI_PHON>
<NSF_ID>000826917</NSF_ID>
<StartDate>12/17/2020</StartDate>
<EndDate>01/07/2021</EndDate>
<RoleCode>Former Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Joseph</FirstName>
<LastName>Dodd-o</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Joseph Dodd-o</PI_FULL_NAME>
<EmailAddress>jd@saphtx.com</EmailAddress>
<PI_PHON>4842260565</PI_PHON>
<NSF_ID>000846528</NSF_ID>
<StartDate>01/07/2021</StartDate>
<EndDate>07/16/2021</EndDate>
<RoleCode>Former Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Corey</FirstName>
<LastName>Heffernan</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Corey Heffernan</PI_FULL_NAME>
<EmailAddress>corey@saphtx.com</EmailAddress>
<PI_PHON>9739438314</PI_PHON>
<NSF_ID>000858594</NSF_ID>
<StartDate>07/16/2021</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>SAPHTX, INC.</Name>
<CityName>NEWARK</CityName>
<ZipCode>071024113</ZipCode>
<PhoneNumber>6786131386</PhoneNumber>
<StreetAddress>50 Rector St</StreetAddress>
<StreetAddress2><![CDATA[Suite 1403]]></StreetAddress2>
<CountryName>United States</CountryName>
<StateName>New Jersey</StateName>
<StateCode>NJ</StateCode>
<CONGRESSDISTRICT>10</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>NJ10</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>116901635</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>SAPHTX, INC.</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[NEW JERSEY INSTITUTE OF TECHNOLOGY]]></Name>
<CityName>Newark</CityName>
<StateCode>NJ</StateCode>
<ZipCode>071033515</ZipCode>
<StreetAddress><![CDATA[138 Warren St, LSEB 316]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>New Jersey</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>10</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>NJ10</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>1505</Code>
<Text>STTR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<ProgramReference>
<Code>1982</Code>
<Text>BIOLOGICAL CHEMISTRY</Text>
</ProgramReference>
<Appropriation>
<Code>0121</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2021~255933</FUND_OBLG>
</Award>
</rootTag>
